

To view this email as a web page, go [here](#).

[View in your browser](#)




INNOVATION AND COMMERCIALIZATION

Sept. 4, 2024

OHSU Innovates

NEWS

Autobahn Therapeutics closes \$100 million investment round



Congratulations to OHSU startup [Autobahn Therapeutics, Inc.](#) on recently

completing a \$100 million Series C financing round! Autobahn spun out of OHSU to clinically advance compounds that mimic thyroid hormones and can cross the blood brain barrier. The compounds were originally developed in the laboratory of [Thomas Scanlan, Ph.D.](#) Proceeds from the Series C will be used to commence two Phase 2 clinical trials for the company's lead program, ABX-002 for the treatment of patients with major depressive disorder (MDD) and patients with bipolar disorder depression. Read more about the research and investment in the [OHSU News story](#).

Collaborating for a preventative treatment for malaria

SRI International and the laboratory of OHSU researcher [Mike Riscoe, Ph.D.](#), are working on a collaborative project to develop a new malaria treatment that could provide months of protection with a single injection. Riscoe was awarded the 2024 Career Innovation Award from OHSU Innovates for his successful career as an innovator focused on new therapeutic strategies for infectious diseases. Read more about the recent publication and ongoing research below in the [SRI press release](#).

OHSU research brings hope for a universal flu vaccine

A recent publication in Nature Communications from [Jonah Sacha, Ph.D.](#), and colleagues highlights work to develop a universal influenza vaccine — a so-called “one and done” vaccine that confers lifetime immunity against an evolving virus. The vaccine is based on the cytomegalovirus, or CMV, vaccine platform developed at the OHSU Vaccine and Gene Therapy Institute, which also recently showed promise for targeting cancer cells. Read more about the research in the [OHSU News story](#).

ANNOUNCEMENTS

OHSU's newest certified licensing professional

Congratulations to Lisa Lukaesko, Ph.D., on achieving her Certified Licensing Professional credential! In her role as Technology Development Manager at OHSU Technology Transfer, Lisa manages the advancement of OHSU technologies to market, overseeing their evaluation, intellectual property protection, licensing and other commercialization activities.

Learn how to accelerate your idea into patient impact

The Biomedical Innovation Program Commercial Readiness Program is now accepting applications for its fall cohort. This six-week course is an evidence-based experience that will take you out of your comfort zone to connect with potential customers and provide you with a competitive business case for future funding, partnership, and translational science opportunities. Applications are due Friday, Sept. 20 and more details are in the [program flyer](#).

FUNDING OPPORTUNITY

BIP now accepting applications for medical device, software and diagnostic technologies

The Biomedical Innovation Program, or BIP, supports the development and commercialization of novel and innovative technologies which aim to

improve healthcare delivery. BIP grants will be awarded on a competitive basis, with budgets not exceeding \$40,000. Additionally, each awardee will be assigned a project manager and a mentor to advise and help accelerate their project towards commercialization. Letters of intent are due Wednesday, Sept. 18. Find more details about how to apply in the [Request for Applications](#).

FEATURED EVENTS

Advancing Care: Non-Profits Driving Rare Disease Innovation

Join us for the next installment of the OHSU Innovates Speaker Series, which will feature the pioneering efforts of the Raiden Science Foundation and the Spoonbill Foundation. This virtual seminar will delve into the innovative approaches these non-profit organizations are employing to overcome traditional research barriers and advance treatments for rare genetic diseases.

WHEN	Wednesday, Oct. 30 9–10 a.m. PDT
-------------	--

WHERE	Virtual
--------------	----------------

COST	Free, register online
-------------	---------------------------------------

Biotech Summit and Innovation Showcase

The Biotech Summit and Innovation Showcase brings together industry executives, scientists, entrepreneurs, and policymakers to celebrate our region's thriving bioscience sector and identify ways our public and private institutions can collaborate to accelerate future innovation and growth. The event includes informational panels, research and company pitches at the Innovation Showcase and the Bio on the Vine winetasting reception. Find more details on the [Oregon Bioscience Association website](#).

WHEN**Tuesday, Oct. 1**

9:30 a.m. - 7:30 p.m. PDT

WHERE**OHSU Knight Cancer Research Building,
2720 S Moody Ave., Portland**

WHOBiotech researchers, students, post-docs, and
entrepreneurs

COST\$75.00 – \$295.00

TECHNOLOGIES

Featured technologies available for licensing

A selection of OHSU-developed technologies available for licensing to industry partners. For more technologies visit the [OHSU Technology Portal](#).

[OHSU 3234](#) - Combination therapy for the treatment of triple negative

breast cancer

[OHSU 3321](#) - Machine-learning based forecasting of visual field deficits for glaucoma management

[OHSU 3213](#) - Protease Activity Sensing Probes For Early Detection and Prognosis of Pancreatic Cancer

Newly Licensed or Optioned OHSU Technologies

Congratulations to the inventors of these technologies, which were recently licensed or optioned to outside partners.

[OHSU 1771](#) - Materials from the BioLibrary

OHSU 2363 - Cypor knockdown for hepatocyte selection ([Markus Grompe, M.D.](#), [Amita Tiyaboonthai, Ph.D.](#), Anne Vonada)

OHSU 2518, Self-cleaving guide-strand RNA for cell type-specific genome editing ([Markus Grompe, M.D.](#), [Amita Tiyaboonthai, Ph.D.](#))

[OHSU 3108](#) - De novo peptide sequencer ([Bruce Branchaud, Ph.D.](#), [Yu-Jui \(Roger\) Chiu, Ph.D.](#), [Mingchong Dai, Ph.D.](#), [Nicholas Groves, Ph.D.](#), [Andy Mendoza, Srivathsan Ranganathan, Ph.D.](#), [Kevin Schilling, Ph.D.](#), [Eugene Tu](#))

[OHSU 3194](#) - Rapid Antibody Conjugation Technique ([Michael Brasino, Ph.D.](#), [Mingchong Dai, Ph.D.](#), [Matthew Rames, Ph.D.](#), [Srivathsan Ranganathan, Ph.D.](#), [Gulsu Sener, Ph.D.](#), [Kai Tao, Ph.D.](#))

OHSU 3202 - RiboCypher A549 and BEAS-2B data – RNA (raw and processed), translated RNA sequences (FASTA), identified peptide hits, DeepImmuno, mhcFlurry predicted peptide hits ([Jessie May Cartier](#),

[Matthew Chang, Ph.D.](#), [Mark Flory, Ph.D.](#))

U.S. Patents Issued

Congratulations to the OHSU inventors of these recently issued U.S. patents.

[Patent 12,030,858](#) - PARP Inhibitors For Treating Cancer And Asthma

[Patent 12,030,893](#) - Near-infrared Nerve-sparing Benzo[c]phenoxazine Fluorophores

[Patent 12,0502,57](#) - Real Time Monitoring And Prediction Of Motion In MRI

[Patent 12,059,500](#) - Therapeutic Constructs For Co-delivery Of Mitotic Kinase Inhibitor And Immune Checkpoint Inhibitor

Researchers in New Industry Funded Research Projects

Congratulations to the Principal Investigators of new non-clinical industry sponsored research.

Evaluation of Inhibitors to Prevent Catheter-Related Thrombosis ([Michael Cohen, Ph.D.](#))

Elucidating mechanism of action of Tausled-like Kinase Activity ([Joseph Shatzel, M.D., M.C.R.](#))

SPONSORS

Thank you to our current sponsors for their support of OHSU Innovates!



Questions? Contact us at innovates@ohsu.edu

This bi-monthly publication is created in collaboration with OHSU Technology Transfer, OHSU Collaborations and Entrepreneurship, Oregon Clinical and Translational Research Institute and the Knight Cancer Institute.

©2024 OHSU

This email was sent by OHSU
3181 S.W. Sam Jackson Park Rd.
Portland, OR, 97239, US

This email was sent to: trueca@ohsu.edu

[Unsubscribe](#) | [Manage subscriptions](#) | [Update profile](#)

[OHSU email terms of service](#) | [OHSU privacy policy](#)